Skip to main content
. 2016 Oct 10;8(5):7328–7335. doi: 10.18632/oncotarget.12551

Table 1. Clinical-pathological patients’characteristics according to mutation variants and line of therapy. PR: partial response; PD: progression disease; SD: stable disease.

PATIENT AGE SEX TISSUE HISTOTYPE TIME to metastasis I-line THERAPY RESPONSE after I-line therapy II-line THERAPY RESPONSE after II-line therapy III-line THERAPY Long survivors GENE/MUTATION/VARIANTS
1 74 M kidney ccRCC 0 Sorafenib PR Sorafenib - - - FGFR3 VHL1 PTEN
diaphragm FGFR3 VHL1 PTEN
2 56 F kidney 27 Sunitinib PR Everolimus - - - VHL1 MET
lung ccRCC VHL1 MET
3 59 M adrenal gland 0 Sorafenib PD Sorafenib - - -
kidney ccRCC
4 48 F liver ccRCC 0 Sorafenib PD Sorafenib - - -
5 66 F kidney ccRCC 1 Sunitinib PD - - - - 6 64 M kidney ccRCC 41 Sorafenib PR Everolimus - - -
pancreas
7 58 M kidney ccRCC 37 Sunitinib SD Everolimus - - -
JAK3 lung JAK3
8 50 M kidney ccRCC 53 Sunitinib PD - - + 59mo ERBB4
9 46 M kidney ccRCC 0 Sunitinib PD Sarafenib PD - -
10 35 M lymph-node pRCC 13 Sunitinib PD - - -
11 51 M kidney pRCC 11 Sunitinib SD Everolimus PD Sorafenib - APC CDKN2A
12 74 M kidney ccRCC 9 Sunitinib SD Everolimus PD - -
13 46 M kidney (rhadboid component) ccRCC 14 Sunitinib SD Everolimus PD Sorafenib LFU 30 mo EGFR RB1
liver PTEN
14 66 M omentum ccRCC 32 Sorafenib SD - - -
15 55 M kidney (rhadboid component) ccRCC 0 Temsirolimus PD Sunitinib - - TP53
kidney VHL1
16 68 M kidney ccRCC 9 Sunitinib SD - - + 27 mo
kidney pRCC PTEN
17 62 M kidney (rhadboid component) ccRCC 0 Sunitinib PD Everolimus PD Sorafenib - FGFR3 VHL1
kidney FGFR3 VHL1
18 37 F kidney (sarcomatoid component) ccRCC 0 Sunitinib PD Everolimus PD Sorafenib - VHL1 JAK3
kidney (rhadboidcomponent) VHL1 JAK3
19 79 F kidney ccRCC 14 Sunitinib SD Axitinib SD Sorafenib - VHL1
20 34 M kidney ccRCC 0 Sunitinib PR - - + 6mo VHL 1
21 70 M lymph node ccRCC 36 Sorafenib PD Everolimus - + 60mo
22 62 M liver pRCC 0 Sunitinib PD Everolimus PD Sorafenib - TP53